The FDA approved Guardant Health's Shield blood test for colon cancer screening, making it likely to be covered by Medicare and private insurers. It is effective at detecting later-stage cancers but not early-stage polyps. A positive result requires follow-up with a colonoscopy. Doctors see potential for increased screening rates, but its impact on reducing mortality remains to be seen.
The FDA approved Guardant Health's Shield blood test for colon cancer screening, making it likely to be covered by Medicare and private insurers. It is effective at detecting later-stage cancers but not early-stage polyps. A positive result requires follow-up with a colonoscopy. Doctors see potential for increased screening rates, but its impact on reducing mortality remains to be seen.
टिप्पणियाँ
एक टिप्पणी भेजें